The European Medicines Agency’s scientific committee for human medicines (CHMP) has issued a positive opinion on a Type II variation to the product information for daratumumab in its subcutaneous formulation.
According to Johnson & Johnson Innovative Medicine, this makes it the first injectable oncology medicine in Europe to be recommended for self-administration.
BREAKING